Risk of bleeding after VTE

Major bleeding events are feared and potentially fatal complications of anticoagulant therapy in patients with venous thromboembolism (VTE). Even though several clinical risk factors are associated with major bleeding risk, the predictive power of currently available risk assessment models remain limited. The aim of this project was to identify biomarkers of major bleeding risk during the first year after an incident VTE. We used data from the VTE registry in the Tromsø study. 

Principal Investigator: John-Bjarne Hansen

Project members: Håkon S. Johnsen, Sigrid K. Brækkan, Vania M. Morelli, Esben Bjøri

Publications:

Johnsen et al. Platelet count and risk of major bleeding in venous thromboembolism. Platelets. 2021;32:444-52.

Johnsen et al. Prothrombotic genotypes and risk of major bleeding in patients with incident venous thromboembolism. Thromb Res. 2020;191:82-9.

Johnsen et al. D-Dimer Measured at Diagnosis of Venous Thromboembolism is Associated with Risk of Major Bleeding. TH Open. 2019;3:e77-e84.

North Norwegian Health Authority

MD/PhD Programme UiT (Forskerlinjen)